Lil­ly will test its weight loss drug di­rect­ly against No­vo Nordisk's We­govy

With tens of bil­lions of dol­lars on the line and peo­ple scram­bling to get the drug, Eli Lil­ly is plan­ning to start test­ing its weight loss treat­ment can­di­date in a head-to-head clin­i­cal tri­al against No­vo Nordisk’s We­govy this month.

Lil­ly is plan­ning to seek a fast-track la­bel ex­pan­sion for its type 2 di­a­betes drug Moun­jaro (tirzepatide) to in­clude obe­si­ty. Pit­ting it di­rect­ly against its com­peti­tor could give pre­scribers in­sight in­to which drug is bet­ter for pa­tients. The 700-per­son Phase II­Ib clin­i­cal tri­al, dubbed SUR­MOUNT-5, is slat­ed to wrap up in Feb­ru­ary 2025, ac­cord­ing to a new study list­ed last Fri­day on clin­i­cal­tri­ It was first re­port­ed by Fierce Phar­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.